Research Development
Staff Publications
Sign in using NHS OpenAthens to access our Knowlege Alerts as well as other useful online resources.
Staff Publications
Research Development
Find out what your colleagues have been writing. This section features articles published by staff working for St Helens and Knowsley Teaching Hospitals and Halton, Knowsley and St Helens community staff.
Had something published and it's not included here? Let us know by completing this form.
Resources pertaining to writing for a publication and how to get published can be found by clicking here.
No results for this category.
Abstract During the Covid-19 pandemic, ibrutinib +/- rituximab was approved in England for initial treatment of mantle cell lymphoma (MCL) instead of immunochemotherapy. As limited data are available in this setting, we conducted an observational cohort study evaluating safety and efficacy. Adults receiving ibrutinib +/- rituximab for untreated MCL were..
Published: | 21/12/2023 |
Authors: | Nicholson T |
Background Ibrutinib (IBR) is an oral covalent Bruton tyrosine kinase inhibitor (BTKi), licensed for treatment of relapsed or refractory mantle cell lymphoma (MCL). Under NHS interim Covid-19 agreements in England, IBR with or without rituximab (R) was approved for the frontline treatment for MCL patients (pts) as a safer alternative..
Published: | 14/06/2022 |
Authors: | Nicholson T |
Summary Idelalisib (IDL) is an oral first-in-class phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for chronic lymphocytic leukaemia (CLL) alongside rituximab (R) since 2014. However, little data exist on routine practice. The RETRO-idel was a protocol-led, retrospective study of 110 patients [n = 27 front-line (1L)] who received IDL-R. The primary end-point was clinical..
Published: | 08/07/2021 |
Authors: | Nicholson T |
Patients with myeloproliferative neoplasms (MPN) are at an increased risk of second primary malignancies (SPM) compared with matched‐controls and the general population. The Surveillance, Epidemiology and End Results (SEER) database (US cancer registries) reported that patients with primary myelofibrosis (PMF) had an incidence of SPM of 5·3% after a median..
Published: | 01/05/2020 |
Authors: | Nicholson T |
We present a previously unreported case of rapidly progressing, destructive shoulder arthropathy as an initial presentation of chronic phase chronic myeloid leukaemia. This patient initially presented to clinic for consideration of an arthroplasty for symptom relief; however, her loss to follow-up yielded a rapid progression of her symptoms. Bone marrow..
Published: | 26/06/2019 |
Authors: | Connolly S, Howard J, MacKenzie B, Nicholson T, |
Abstract In 2016, the NIHR Haematology National Speciality Group founded a pilot programme to develop the clinical research skills of Haematology trainees within Non‐Malignant Haematology (NMH). This unique initiative has since been rolled out successfully throughout CRNs nationwide and equips Haematology trainees with the skills to become future leaders in..
Published: | 05/06/2018 |
Authors: | Loizou E, Nicholson T |
BACKGROUND The level of anticoagulation in response to a fixed-dose regimen of warfarin is difficult to predict during the initiation of therapy. We prospectively compared the effect of genotype-guided dosing with that of standard dosing on anticoagulation control in patients starting warfarin therapy. METHODS We conducted a multicenter, randomized, controlled..
Published: | 19/07/2016 |
Authors: | Nicholson T |
No results for this category.
No results for this category.
No results for this category.
No results for this category.